Abstract
Infections caused by hepatitis C virus (HCV) are a significant worldwide health problem for which novel therapies are urgently needed. One attractive and viable therapeutic target is HCV NS5B RNA dependent RNA polymerase (RdRp) since it is essential for the replication of the viral genome of HCV. The hunt for nonnucleoside inhibitors (NNIs) of HCV NS5B polymerase has led to the identification of several allosteric pockets. However, because the topographical features of these binding sites vary across and even within diverse HCV genotypes, the discovery of new antiviral drugs capable of inhibiting HCV RdRp in the face of variable binding pockets becomes a challenging endeavor. This review focuses on recent accomplishments in the development of new NNIs of HCV NS5B polymerase and on their binding mechanisms to the respective allosteric pockets. Potential difficulties surrounding the discovery of future NNIs targeted to different allosteric pockets of HCV NS5B and to HCV NS5B from different genotypes are also discussed.
Keywords: HCV NS5B polymerase, Allosteric pocket, Nonnucleoside inhibitors, Genotypes, Structure activity relationships
Current Bioactive Compounds
Title: Multiple Allosteric Pockets of HCV NS5B Polymerase and its Inhibitors: A Structure Based Insight
Volume: 4 Issue: 2
Author(s): Tanaji T. Talele
Affiliation:
Keywords: HCV NS5B polymerase, Allosteric pocket, Nonnucleoside inhibitors, Genotypes, Structure activity relationships
Abstract: Infections caused by hepatitis C virus (HCV) are a significant worldwide health problem for which novel therapies are urgently needed. One attractive and viable therapeutic target is HCV NS5B RNA dependent RNA polymerase (RdRp) since it is essential for the replication of the viral genome of HCV. The hunt for nonnucleoside inhibitors (NNIs) of HCV NS5B polymerase has led to the identification of several allosteric pockets. However, because the topographical features of these binding sites vary across and even within diverse HCV genotypes, the discovery of new antiviral drugs capable of inhibiting HCV RdRp in the face of variable binding pockets becomes a challenging endeavor. This review focuses on recent accomplishments in the development of new NNIs of HCV NS5B polymerase and on their binding mechanisms to the respective allosteric pockets. Potential difficulties surrounding the discovery of future NNIs targeted to different allosteric pockets of HCV NS5B and to HCV NS5B from different genotypes are also discussed.
Export Options
About this article
Cite this article as:
Talele T. Tanaji, Multiple Allosteric Pockets of HCV NS5B Polymerase and its Inhibitors: A Structure Based Insight, Current Bioactive Compounds 2008; 4 (2) . https://dx.doi.org/10.2174/157340708785294217
DOI https://dx.doi.org/10.2174/157340708785294217 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Organ-Specific Pharmacological Strategies Interfering With Signaling Pathways In Inflammatory Disorders/Autoimmune Disorders
Current Signal Transduction Therapy Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands
Current Medicinal Chemistry Recent Advances in Protein and Peptide Drug Delivery Systems
Current Drug Delivery CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry “Bridge Proteins” Link Inflammation and Metabolic Diseases: Potential Targets for Therapeutics
Current Protein & Peptide Science Oxidative Stress in Allergic and Inflammatory Skin Diseases
Current Drug Targets - Inflammation & Allergy Exosomes in Sepsis and Inflammatory Tissue Injury
Current Pharmaceutical Design Review Metabolomics: A New Approach to Drug Delivery in Perinatology
Current Medicinal Chemistry Endocannabinoids in Appetite Control and the Treatment of Obesity
CNS & Neurological Disorders - Drug Targets (Section B: Integrated Function of Drug Transporters In Vivo) Drug Transport at the Blood-Brain Barrier and the Choroid Plexus
Current Drug Metabolism Potential Novel Anxiolytic Drugs
Current Pharmaceutical Design Editorial (Thematic Issue: Modulations and their Biological Functions of Protein-Biomolecule Interactions)
Current Topics in Medicinal Chemistry Fatty Acid Amide Hydrolase Inhibitors – Progress and Potential
CNS & Neurological Disorders - Drug Targets Mechanisms and Consequences of Protein Aggregation: The Role of Folding Intermediates
Current Protein & Peptide Science Bipolar Affective Disorder in Young People: A Review
Adolescent Psychiatry Targeting Bcl-2 Family of Proteins: An Important Strategy in Cancer Therapeutics
Current Chemical Biology Novel Targets of Vitamin D Activity in Bone: Action of the Vitamin D Receptor in Osteoblasts, Osteocytes and Osteoclasts
Current Drug Targets Sleep-Inducing Factors
CNS & Neurological Disorders - Drug Targets Dysglycemia and Abdominal Obesity
Current Vascular Pharmacology Cell-Permeable Peptide Inhibitor of c-Jun NH2-Terminal Kinase for the Treatment of Diabetes
Current Bioactive Compounds